Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 723158, 6 pages
Research Article

Folic Acid-Chitosan Conjugated Nanoparticles for Improving Tumor-Targeted Drug Delivery

1Central Laboratory for Science and Technology, Liaoning Medical University, Jinzhou 121000, China
2College of Veterinary Medicine, Liaoning Medical University, Jinzhou 121000, China
3National Vaccine & Serum Institute, Beijing 100024, China
4College of Pharmacy, Liaoning Medical University, Jinzhou 121000, China

Received 6 July 2013; Revised 28 August 2013; Accepted 10 September 2013

Academic Editor: Fabio Sonvico

Copyright © 2013 Huijuan Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To prepare folic acid-chitosan conjugated nanoparticles (FA-CS NPs) and evaluate their targeting specificity on tumor cells. Methods. Chitosan (CS) NPs were prepared by ionic cross linking method, and folic acid (FA) was conjugated with CS NPs by electrostatic interaction. The properties of NPs were investigated, and doxorubicin hydrochloride (Dox) as a model drug was encapsulated for investigating drug release pattern in vitro. The cytotoxicity and cellular uptake of FA-CS NPs were also investigated. Results. The results reveal that the obtained FA-CS NPs were monodisperse nanoparticles with suitable average size and positive surface charge. Dox was easily loaded into FA-CS NPs, and the release pattern showed a long and biphasic drug release. Noticeable phagocytosis effect was observed in the presence of rhodamine B-labeled FA-CSNPs when incubating with the folate receptor-positive SMMC-7221 cells. Conclusion. Compared with the unmodified CS NPs, FA-CS NPs showed much higher cell uptaking ability due to the known folate-receptor mediated endocytosis. FA-CS NPs provide a potential way to enhance the using efficiency of antitumor drug by folate receptor mediated targeting delivery.